2023年7月,美国心脏协会(American Heart Association,AHA)、美国心脏病学会(American College of Cardiology,ACC)等六个学术组织联合发布了慢性冠心病(chronic coronary disease,CCD)管理指南.通过梳理最新的科学数据,指南再次强调了健康饮食、定期体育锻炼和戒烟对心血管健康的重要性,常规检测仅限于临床或功能状态发生变化的患者.在CCD的临床治疗方面,缩小了 β受体阻滞剂(beta-blockers,BB)的应用范围,更新了 3种药物的使用建议,包括钠-葡萄糖共转运蛋白2抑制剂(sodium glucose cotransporter 2 inhibitors,SGLT2i)、胰高血糖素样肽-1(glucagon-likepeptide-1,GLP-1)受体激动剂和贝派地酸.本文就《2023年AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠心病管理指南》进行解读.
Interpretation of 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
In July 2023,six scientific organizations,including the American Heart Association(AHA)and the American College of Cardiology(ACC),jointly released the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease.By reviewing the latest scientific data,the guideline reemphasized the importance of a healthy diet,regular physical activity and smoking cessation in cardiovascular health.Routine testing is limited to patients with changes in clinical or functional status.Regarding the clinical management of CCD,the guideline limited the use of beta-blockers(BB)and updated recommendations for the usage of three drugs,including sodium-glucose cotransporter-2 inhibitors(SGLT2i),glucagon-like peptide-1(GLP-1)receptor agonists,and bempedoic acid.
万方数据
维普
